197 related articles for article (PubMed ID: 25198178)
1. Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes.
Gordon RR; Wu M; Huang CY; Harris WP; Sim HG; Lucas JM; Coleman I; Higano CS; Gulati R; True LD; Vessella R; Lange PH; Garzotto M; Beer TM; Nelson PS
PLoS One; 2014; 9(9):e104271. PubMed ID: 25198178
[TBL] [Abstract][Full Text] [Related]
2. Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15.
Huang CY; Beer TM; Higano CS; True LD; Vessella R; Lange PH; Garzotto M; Nelson PS
Clin Cancer Res; 2007 Oct; 13(19):5825-33. PubMed ID: 17908975
[TBL] [Abstract][Full Text] [Related]
3. Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.
Garzotto M; Higano CS; O'Brien C; Rademacher BL; Janeba N; Fazli L; Lange PH; Lieberman S; Beer TM
Cancer; 2010 Apr; 116(7):1699-708. PubMed ID: 20143429
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates.
Bergstrom CP; Ruffell B; Ho CM; Higano CS; Ellis WJ; Garzotto M; Beer TM; Graff JN
Anticancer Drugs; 2017 Jan; 28(1):120-126. PubMed ID: 27669423
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer.
Vuky J; Corman JM; Porter C; Olgac S; Auerbach E; Dahl K
Oncologist; 2013 Jun; 18(6):687-8. PubMed ID: 23740935
[TBL] [Abstract][Full Text] [Related]
6. Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis.
Wu JB; Shao C; Li X; Li Q; Hu P; Shi C; Li Y; Chen YT; Yin F; Liao CP; Stiles BL; Zhau HE; Shih JC; Chung LW
J Clin Invest; 2014 Jul; 124(7):2891-908. PubMed ID: 24865426
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.
Ross RW; Galsky MD; Febbo P; Barry M; Richie JP; Xie W; Fennessy FM; Bhatt RS; Hayes J; Choueiri TK; Tempany CM; Kantoff PW; Taplin ME; Oh WK
Cancer; 2012 Oct; 118(19):4777-84. PubMed ID: 22282219
[TBL] [Abstract][Full Text] [Related]
8. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.
Febbo PG; Richie JP; George DJ; Loda M; Manola J; Shankar S; Barnes AS; Tempany C; Catalona W; Kantoff PW; Oh WK
Clin Cancer Res; 2005 Jul; 11(14):5233-40. PubMed ID: 16033841
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer.
Garzotto M; Myrthue A; Higano CS; Beer TM
Urol Oncol; 2006; 24(3):254-9. PubMed ID: 16678060
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer.
Beer TM; Garzotto M; Lowe BA; Ellis WJ; Montalto MA; Lange PH; Higano CS
Clin Cancer Res; 2004 Feb; 10(4):1306-11. PubMed ID: 14977829
[TBL] [Abstract][Full Text] [Related]
12. Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.
Beltran H; Wyatt AW; Chedgy EC; Donoghue A; Annala M; Warner EW; Beja K; Sigouros M; Mo F; Fazli L; Collins CC; Eastham J; Morris M; Taplin ME; Sboner A; Halabi S; Gleave ME
Clin Cancer Res; 2017 Nov; 23(22):6802-6811. PubMed ID: 28842510
[No Abstract] [Full Text] [Related]
13. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?
Michels J; Montemurro T; Murray N; Kollmannsberger C; Nguyen Chi K
Cancer; 2006 Mar; 106(5):1041-6. PubMed ID: 16456811
[TBL] [Abstract][Full Text] [Related]
14. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer.
Friedman J; Dunn RL; Wood D; Vaishampayan U; Wu A; Bradley D; Montie J; Sarkar FH; Shah RB; Hussain M
J Urol; 2008 Mar; 179(3):911-5; discussion 915-6. PubMed ID: 18207190
[TBL] [Abstract][Full Text] [Related]
16. Targeting monoamine oxidase A in advanced prostate cancer.
Flamand V; Zhao H; Peehl DM
J Cancer Res Clin Oncol; 2010 Nov; 136(11):1761-71. PubMed ID: 20204405
[TBL] [Abstract][Full Text] [Related]
17. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
Oudard S; Legrier ME; Boyé K; Bras-Gonçalves R; De Pinieux G; De Cremoux P; Poupon MF
J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial.
Kim WY; Whang YE; Pruthi RS; Baggstrom MQ; Rathmell WK; Rosenman JG; Wallen EM; Goyal LK; Grigson G; Watkins C; Godley PA
Urol Oncol; 2011; 29(6):608-13. PubMed ID: 20022268
[TBL] [Abstract][Full Text] [Related]
19. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.
Marín-Aguilera M; Codony-Servat J; Reig Ò; Lozano JJ; Fernández PL; Pereira MV; Jiménez N; Donovan M; Puig P; Mengual L; Bermudo R; Font A; Gallardo E; Ribal MJ; Alcaraz A; Gascón P; Mellado B
Mol Cancer Ther; 2014 May; 13(5):1270-84. PubMed ID: 24659820
[TBL] [Abstract][Full Text] [Related]
20. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
